BiomX Inc.

BiomX Inc. (NYSE American: PHGE) is a clinical-stage biopharmaceutical company focused on the discovery and development of phage-based therapies targeting bacterial diseases. The company went public in October 2019 through a business combination with Chardan NexTech Acquisition Corp., a SPAC sponsored by Chardan Capital Markets. BiomX's pipeline centers on bacteriophage products for chronic and acute infections, with programs spanning areas including diabetic foot osteomyelitis and inflammatory conditions. On August 11, 2026, the company filed a DEF 14A definitive proxy statement with the SEC, accession number 0001213900-26-087834, in connection with a stockholder meeting. Visit SpacDesk and sign up for full data, filings history, and deal analytics on BiomX and hundreds of other SPAC-originated public companies.